SCHEMBL1365040

SCHEMBL1365040

Cc1cc(N)cc(S(=O)(=O)O)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.46
TDP1 Q9NUW8 5/20 0.46
HSD17B10 Q99714 3/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
KDM4E B2RXH2 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
POLB P06746 2/20 0.42
GAA P10253 2/20 0.42
MAPT P10636 2/20 0.42
RECQL P46063 2/20 0.42
CASP6 P55212 2/20 0.42
ELAVL1 Q15717 1/20 0.42
RAPGEF4 Q8WZA2 1/20 0.40
SUMO2 P61956 2/20 0.38
SUMO1 P63165 2/20 0.38
SENP7 Q9BQF6 2/20 0.38
SENP2 Q9HC62 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11337312 0.89 ALDH1A1 (0.50) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL30922153 0.83 ALDH1A1 (0.46) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL9680119 0.83 TDP1 (0.47) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL10847621 0.83 ALDH1A1 (0.46) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL15449420 0.82 ALDH1A1 (0.58) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL2435832 0.81 L3MBTL1 (0.59) ALDH1A1KDM4EL3MBTL1MEN1KMT2A
SCHEMBL176785 0.80 ALDH1A1 (0.44) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL18538523 0.80 ALDH1A1 (0.43) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL2884819 0.78 CA1 (0.42) ALDH1A1TDP1KDM4EL3MBTL1MEN1
SCHEMBL13214335 0.77 ALDH1A1 (0.67) ALDH1A1TDP1HSD17B10CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49569-E1 Alkylamine derivative EA PHARMA CO., LTD. (JP) 2023-07-04 US disclosed
EP-2546231-B1 ALKYLAMINE DERIVATIVE EA PHARMA CO LTD (JP) 2018-11-07 EP disclosed
US-9561216-B2 Alkylamine derivative EA PHARMA CO., LTD. (JP) 2017-02-07 US disclosed
US-20160101091-A1 ALKYLAMINE DERIVATIVE AJINOMOTO CO., INC. (JP) 2016-04-14 US disclosed
US-9253997-B2 Alkylamine derivative AJINOMOTO CO., INC. (JP) 2016-02-09 US disclosed
US-9150505-B2 Prophylactic or therapeutic agent for diabetes or obesity AJINOMOTO CO., INC. (JP) 2015-10-06 US disclosed
US-20130237702-A1 ALKYLAMINE DERIVATIVE AJINOMOTO CO., INC. (JP) 2013-09-12 US disclosed
US-20130072491-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY AJINOMOTO CO., INC. (JP) 2013-03-21 US disclosed
EP-2546231-A1 ALKYLAMINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2013-01-16 EP disclosed
EP-2543660-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY Ajinomoto Co., Inc. (JP) 2013-01-09 EP disclosed
WO-2005121204-A2 POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR CANON KABUSHIKI KAISHA (JP) 2005-12-22 WO disclosed
WO-2005121904-A1 CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS CANON KABUSHIKI KAISHA (JP) 2005-12-22 WO disclosed
WO-2005121205-A2 POLYHYDROXYALKANOATE HAVING ESTER GROUP, CABOXYL GROUP, AND SULFONIC GROUP, AND METHOD OF PRODUCING THE SAME CANON KABUSHIKI KAISHA (JP) 2005-12-22 WO disclosed
WO-2005108441-A2 POLYMER HAVING A SULFONIC GROUP OR A SULFONATE GROUP AND AN AMIDE GROUP AND METHOD OF PRODUCING SAME CANON KABUSHIKI KAISHA (JP) 2005-11-17 WO disclosed
EP-1579277-A1 POLYHYDROXYALKANOATE CONTAINING AMIDE GROUP, SULFONIC GROUP, AND SULFONATE ESTER GROUP, METHOD FOR PRODUCING THE SAME, AND CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS Canon Kabushiki Kaisha (JP) 2005-09-28 EP disclosed
EP-1579276-A1 NOVEL POLYHYDROXYALKANOATE HAVING AMIDE, SULFONIC ACID OR SULFONATE ESTER GROUP, CHARGE CONTROL AGENT AND TONER CANON KABUSHIKI KAISHA (JP) 2005-09-28 EP disclosed
WO-2004061530-A1 POLYHYDROXYALKANOATE CONTAINING AMIDE GROUP, SULFONIC GROUP, AND SULFONATE ESTER GROUP, METHOD FOR PRODUCING THE SAME, AND CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS CANON KABUSHIKI KAISHA (JP) 2004-07-22 WO disclosed
WO-2004061529-A1 NOVEL POLYHYDROXYALKANOATE HAVING AMIDE, SULFONIC ACID OR SULFONATE ESTER GROUP, CHARGE CONTROL AGENT AND TONER CANON KABUSHIKI KAISHA (JP) 2004-07-22 WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072491-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY CASR, GPR119, GLP1R ALDH1A1 2305/4885TDP1 4149/4885HSD17B10 2719/4885
US-20160101091-A1 ALKYLAMINE DERIVATIVE CASR, TAAR5, TAAR1 ALDH1A1 2451/4885TDP1 1976/4885HSD17B10 2174/4885
US-20130237702-A1 ALKYLAMINE DERIVATIVE CASR, TAAR5, TAAR1 ALDH1A1 2451/4885TDP1 1976/4885HSD17B10 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.